跳至主要内容
临床试验/NCT00082524
NCT00082524已完成2 期

A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children With Documented Candida or Aspergillus Infections

Merck Sharp & Dohme LLC0 个研究点目标入组 50 人开始时间: 2004年4月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
50
主要终点
The proportion of patients with one or more drug-related clinical or laboratory adverse experience(s)

研究概览

简要总结

This study is an open label, noncomparative study using an investigational agent for the treatment of documented Candida or Aspergillus infections in pediatric patients (ages 3 months-17 years).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Months 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The proportion of patients with one or more drug-related clinical or laboratory adverse experience(s)

次要结局

  • The proportion of patients with a favorable efficacy response to caspofungin therapy in each infection type
  • The proportion of patients who discontinued due to a drug-related AE or who have a serious drug-related AE

研究者

申办方类型
Industry
责任方
Sponsor

相似试验